Growth Metrics

Edwards Lifesciences (EW) Receivables - Net (2016 - 2026)

Edwards Lifesciences has reported Receivables - Net over the past 17 years, most recently at $659.6 million for Q4 2025.

  • For Q4 2025, Receivables - Net rose 8.29% year-over-year to $659.6 million; the TTM value through Dec 2025 reached $659.6 million, up 8.29%, while the annual FY2025 figure was $659.6 million, 8.29% up from the prior year.
  • Receivables - Net for Q4 2025 was $659.6 million at Edwards Lifesciences, down from $693.3 million in the prior quarter.
  • Over five years, Receivables - Net peaked at $817.6 million in Q1 2024 and troughed at $582.2 million in Q4 2021.
  • A 5-year average of $678.4 million and a median of $664.4 million in 2025 define the central range for Receivables - Net.
  • Biggest five-year swings in Receivables - Net: increased 19.98% in 2023 and later decreased 21.05% in 2024.
  • Year by year, Receivables - Net stood at $582.2 million in 2021, then rose by 10.44% to $643.0 million in 2022, then increased by 19.98% to $771.5 million in 2023, then dropped by 21.05% to $609.1 million in 2024, then grew by 8.29% to $659.6 million in 2025.
  • Business Quant data shows Receivables - Net for EW at $659.6 million in Q4 2025, $693.3 million in Q3 2025, and $697.0 million in Q2 2025.